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spina bifida. In studies of births in Great Britain prior
to 1979, the prevalence of spina bifida at birth was
within the range of 1.5–4.1 per 1,000 births, and, in
studies in the early 1980s, the prevalence was within the
range of 0.7–1.9 per 1,000 births (Little and Elwood
1992). Some of these infants would have been stillborn.
For example, in Northern Ireland during the period
1974–79, 15.5% of 569 cases of spina bifida or encepha-
lacoele were stillborn (Little and Nevin 1989). In Glas-
gow and Liverpool during the period 1980–92, when
fetuses from terminated pregnancies were excluded,
16% of 262 cases of spina bifida were recorded to have
resulted in fetal deaths (EUROCAT Working Group
1995). Therefore, it appears that the proportion of cases
of childhood cancer with neural tube defects is similar
to what would be expected on the basis of data on the
prevalence of these defects at birth, in Great Britain.
In the study by Narod et al. (1997), eight of the chil-
dren with tumors of the brain or of the spinal cord were
recorded as having spina bifida, compared with the 5.6
expected on the basis of the frequency of spina bifida
among children with other types of cancer in Great Brit-
ain and with the 2.4 expected on the basis of the data
for British Columbia. Again, the proportion of children
with tumors of the brain or of the spinal cord who were
recorded as having spina bifida (1.7 per 1,000 births)
would appear to be within the range of prevalences at
birth reported for Great Britain during the period in
which the children included in the study by Narod et al.
would have been born. Thus, the study by Narod et al.
does not appear to support the hypothesis of a common
maternal factor for brain tumors and spina bifida.
JULIAN LITTLE
Department of Medicine and Therapeutics
University of Aberdeen
Aberdeen
United Kingdom
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Reply to Little
To the Editor:
My colleagues and I thank Dr. Little (1997 [in this issue])
for his important data. We saw an excess of neural tube
defects in children with cancer, in the United Kingdom,
compared with healthy controls from British Columbia.
It is unclear to what extent the control group from Brit-
ish Columbia was comparable to the children from Brit-
ain, and our approach is inadequate when the baseline
rates of disease differ for the two countries. Unlike the
rates of other malformations, the rate of spina bifida
was not significantly greater in children with solid tu-
mors than in those with leukemia. We agree that our
data do not allow us to conclude that there is an excess
of cancer among children with neural tube defects.
STEVEN NAROD
The Centre for Research in Women’s Health
Toronto
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Lafora Progressive Myoclonus Epilepsy: Narrowing
the Chromosome 6q24 Locus by Recombinations
and Homozygosities
To the Editor:
Lafora disease (LD) is an autosomal recessive and rare
but fatal epilepsy syndrome characterized by stimuli-sen-
sitive myoclonus, absence and grand mal seizures, pro-
gressive intellectual and neurological deterioration, and
periodic acid Schiff (PAS) stain–positive intracellular in-
clusion bodies. Eighty-four years after Gonzalo Lafora
